盘点:JAMA 20年8月原始研究第二期汇总

2020-08-22 MedSci原创 MedSci原创

【1】自由输血阈值并不能降低极低出生体重儿死亡或致残的风险

【1】自由输血阈值并不能降低极低出生体重儿死亡或致残的风险

 

doi:10.1001/jama.2020.10690

 

为了比较自由或限制性红细胞输注策略对死亡或残疾的影响,2011年7月14日至2014年11月14日,研究组在欧洲的36个III/IV级新生儿重症监护病房中,对出生后不到72小时、出生体重在400 g至999 g之间的1013例婴儿进行了一项随机临床试验。根据婴儿的出生胎龄和当前健康状况,将其随机分组,其中492例接受自由红细胞输注阈值,521例接受限制性红细胞输注阈值。共1013例婴儿,出生时中位胎龄为妊娠26.3周,50.2%为女婴,共有928例(91.6%)完成了试验。在自由和限制性输血阈值组的婴儿中,总输血发生率分别为81.3%和60.5%;输血中位数分别为40 mL和19 mL。限制性输血阈值组的婴儿周均红细胞压积比自由输血阈值组高3个百分点。在自由和限制性输血阈值组的婴儿中,主要结局发生率分别为44.4%和42.9%,差异不显著;其中24个月内的死亡率分别为8.3%和9.0%,认知缺陷发生率分别为37.6%和34.4%,脑瘫发生率分别为4.3%和5.6%,均无统计学差异。在自由和限制性输血阈值组的婴儿中,需要手术干预的坏死性小肠结肠炎发生率分别为4.1%和5.4%;支气管肺发育不良的发生率分别为28.4%和26.0%;早产儿视网膜病变的治疗率分别为8.7%和7.7%。两组婴儿的生长发育亦无显著差异。总之,对于出生体重小于1000 g的婴儿,与限制性输血相比,自由输血的策略并不能降低其24个月时死亡或致残的风险。

 

【2】多焦隐形眼镜,三年内能把近视发展速度降低43%

 

doi:10.1001/jama.2020.10834

 

为了验证多焦隐形眼镜是否可降低通过抑制眼睛生长从而延缓近视度数增长,研究人员对 287 名 7-11 岁的近视儿童展开临床调查。研究开始时,这些儿童需要-0.75 到 -5.00 屈光度(屈光度超过-5.00则为高度近视)矫正才能获得清晰的远视。

研究人员将这些儿童随机分配为 3 组,第 1 组佩戴常规单视力隐形眼镜,第 2 组佩戴中聚焦强度(+1.5 屈光度)多焦隐形眼镜,第3组则佩戴高聚焦强度(+2.5 屈光度)多焦隐形眼镜。这些儿童都被要求在白天尽可能多地佩戴隐形眼镜——只要他们觉得舒服就行。此外,所有的儿童都在俄亥俄州立大学、哥伦布大学或休斯顿大学的诊所就诊,以便及时进行回访调查。3年之后,三组儿童的屈光度进展率依次(1→3)为:-1.05,-0.89和-0.60。与此同时,多焦隐形眼镜还会减缓眼镜的生长,三组儿童的眼镜生长变化分别(1→3)为:0.66mm,0.58mm 和 0.42mm。由此看来,与佩戴常规单视力隐形眼镜的儿童相比,另外两组佩戴多焦隐形眼镜的儿童的近视进展更为缓慢,并且只有高强度多焦隐形眼镜才会显著减缓眼睛的生长。

 

【3】抗生素非手术治疗儿童单纯性阑尾炎优于手术治疗

 

doi:10.1001/jama.2020.10888

 

为了确定非手术治疗儿童单纯性阑尾炎的成功率,并比较非手术治疗与手术治疗的致残率、满意度、健康相关生活质量和并发症的差异, 2015年5月至2018年10月,研究组进行了一项多机构、非随机、对照、干预研究,在美国7个州的10家三级儿童医院招募了1068名7-17岁的单纯性阑尾炎儿童,平均年龄为12.4岁,女孩占38%。根据患者和家属选择,370例单独使用抗生素治疗,698例在入院12小时内紧急行腹腔镜阑尾切除术。共有806例(75%)患者接受了完整的随访,其中非手术组284例(77%),手术组522例(75%)。与手术组相比,非手术组的患者更年幼(中位年龄分别为12.3岁和12.5岁),黑人占比高(9.6%和4.9%),其他种族占比高(14.6%和8.7%),看护人具有学士学位的占比高(29.8%和23.5%),接受超声诊断的占比高(79.7%和74.5%)。在治疗逆概率加权(IPTW)后,一年内非手术治疗的成功率为67.1%。非手术组患者一年内的平均失能天数(定义为因阑尾炎相关护理而无法参加所有正常活动的天数)为6.6天,显著少于手术组(10.9天)。在其他16个预先指定的次要指标中,有10个没有显著差异。总之,对于患单纯性阑尾炎的儿童,仅使用抗生素的初始非手术治疗策略的成功率为67.1%,且1年时的失能天数显著少于紧急手术治疗。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=812557, encodeId=d59181255e00, content=很详细,很赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 21:57:30 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812518, encodeId=9326812518ab, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:43 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812389, encodeId=ed638123891e, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:19 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036234, encodeId=f3391036234ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 22 17:38:35 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    很详细,很赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=812557, encodeId=d59181255e00, content=很详细,很赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 21:57:30 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812518, encodeId=9326812518ab, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:43 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812389, encodeId=ed638123891e, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:19 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036234, encodeId=f3391036234ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 22 17:38:35 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    讲的很详细,很有用,赞一个

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=812557, encodeId=d59181255e00, content=很详细,很赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 21:57:30 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812518, encodeId=9326812518ab, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:43 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812389, encodeId=ed638123891e, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:19 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036234, encodeId=f3391036234ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 22 17:38:35 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    很有用,很不错,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=812557, encodeId=d59181255e00, content=很详细,很赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 21:57:30 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812518, encodeId=9326812518ab, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:43 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812389, encodeId=ed638123891e, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:19 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036234, encodeId=f3391036234ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 22 17:38:35 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-22 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0